Skip to main content

Table 3 Clinical assessment and evaluation of the 74 dogs screened at the pre-inclusion visit

From: Six-month field efficacy and safety of the combined treatment of dogs with Frontline Tri-Act® and NexGard Spectra®

Leishmania infantum seropositive dogs

25/74 (33.8%)

Ehrlichia canis seropositive dogs

2/74 (2.7%)

Anaplasma spp. seropositive dogs

1/74 (1.4%)

Gastrointestinal parasite positive dogs

29/74 (39.2%)

Fleas positive dogs

26/74 (35.1%)

Ticks positive dogs

4/74 (5.4%)

Alterations of the haematological parameters

19/74 (25.7%)

Owners not complying with the study protocol

2/74 (2.7%)